Bridgeway Capital Management’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Bridgeway Capital Management's CTNM Position: Q3 2026 in Review
Bridgeway Capital Management sold out of Contineum Therapeutics (CTNM) in Q3 2026, closing a stake of 49,280 shares — an estimated $808K sold.
Bridgeway Capital Management first reported a position in CTNM in Q2 2025 and held it in 5 quarters. The position peaked at $808K in Q2 2026. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Bridgeway Capital Management reported no remaining Contineum Therapeutics position as of Q3 2026 after selling out during the quarter.
- Bridgeway Capital Management sold 49,280 Contineum Therapeutics shares in Q3 2026, an estimated $808K.
- Bridgeway Capital Management first reported a position in Contineum Therapeutics in Q2 2025 and held it in 5 quarters.
- Bridgeway Capital Management's Contineum Therapeutics position peaked at $808K in Q2 2026.
- 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.